News Releases

2024-03-05 09:42:32	YS Biopharma Announces Board Changes and Strategic Leadership Appointments in Chinese Subsidiaries
2024-02-22 15:52:47	YS Biopharma Announces Results of Extraordinary General Meeting held on February 22, 2024
2024-02-16 15:52:02	/C O R R E C T I O N -- YS Biopharma Co., Ltd./
2024-02-16 15:51:25	YS Biopharma Announces Results of Extraordinary General Meeting and Responds to False Statements abo
2024-02-14 15:50:54	YS Biopharma to Hold an Extraordinary General Meeting on February 22, 2024 pursuant to a Shareholder
2024-02-14 15:50:34	YS Biopharma Announces Appointment of New Directors
2024-02-12 15:49:58	YS Biopharma Responds to a Notice of Extraordinary General Meeting of Shareholders of YS Biopharma C
2024-02-09 15:49:18	YS Biopharma Announces US$40 Million Private Placement Financing
2024-01-22 15:48:29	YS Biopharma Announces Unaudited Financial Results for the First Half of Fiscal Year 2024
2024-01-08 15:47:40	YS Biopharma Announces Changes to its Board Committees
2023-12-20 15:47:18	YS Biopharma Responds to Unauthorized Press Release Regarding Extraordinary General Meeting
2023-11-14 15:46:34	Noble Capital Markets Initiates Coverage on YS Biopharma With Outperform Rating and US$5.25 Price Ta
2023-10-31 15:46:08	YS Biopharma Announces Completion of Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Ra
2023-10-26 15:45:34	YS Biopharma Announces Receipt of Nasdaq Notice
2023-09-26 15:45:01	YS Biopharma Announces First Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vac
2023-09-15 15:44:20	YS Biopharma Granted Patent in the U.S. for Immunotherapy Targeting Chronic Hepatitis B Virus Infect
2023-09-05 15:43:47	YS Biopharma to Participate in Citi's 18th Annual Biopharma Conference
2023-08-24 15:43:14	YS Biopharma Announces Purchase of Shares by Company Officers
2023-08-15 15:42:27	YS Biopharma Announces Unaudited Financial Results for the First Quarter of Fiscal Year 2024
2023-08-10 15:37:01	YS Biopharma to Report First Quarter Fiscal Year 2024 Financial Results on August 15, 2023
2023-07-26 15:35:56	YS Biopharma Announces Financial Results for Fiscal Year 2023 Ended March 31, 2023
2023-07-21 15:35:10	YS Biopharma to Report Financial Results for Fiscal Year 2023 on July 26, 2023
2023-06-01 15:34:32	YS Biopharma's PIKA Rabies Vaccine Receives Phase 3 Clinical Trial Approval From Philippines FDA
2023-05-18 15:34:08	YS Biopharma to Participate in the Virtual Benchmark Healthcare House Call Conference on May 23, 202
2023-05-16 15:33:33	YS Biopharma's PIKA Rabies Vaccine Receives Phase 3 Clinical Trial Approval in Pakistan
2023-04-18 15:32:40	YS Biopharma Announces Record Vaccine Revenues and Preliminary Financial Results for FY2023 Ended Ma
2023-03-27 15:31:48	YS Biopharma's PIKA Recombinant COVID-19 Vaccine Demonstrates Superior Antibody Neutralization Respo
2023-03-16 15:31:25	YS BIOPHARMA TO RING THE OPENING BELL AND DEBUT ON NASDAQ
2023-03-14 15:30:39	YS BIOPHARMA AND SUMMIT HEALTHCARE ANNOUNCE SHAREHOLDER APPROVAL OF BUSINESS COMBINATION
2023-02-08 15:29:43	SUMMIT HEALTHCARE ACQUISITION CORP. AND YS BIOPHARMA ANNOUNCE EFFECTIVENESS OF REGISTRATION STATEMEN
2022-11-15 15:29:16	YS Biopharma Received Qualified Person Declaration for Its PIKA COVID-19 Vaccine Facility Equivalent
2022-11-10 15:28:28	YS Biopharma Announces US FDA Clearance Of IND Application For PIKA COVID-19 vaccine
2022-09-29 15:27:58	YS BIOPHARMA TO MERGE WITH NASDAQ-LISTED SUMMIT HEALTHCARE ACQUISITION CORP.
2022-09-08 15:25:14	YishengBio Received Approvals From Philippines and UAE For Phase 2 / 3 Clinical Trials of PIKA Recom
2021-02-24 14:24:52	YishengBio Raises $130 Million in Series B Funding to Accelerate Pipeline Development and Commercial

Print Page

Email Alerts

RSS Feeds

Contact IR

News Releases

Contact Info